Recent Advances in Detection and Diagnosis of Urological Cancers

Urological cancers, inclusive of prostate cancer, bladder cancer, and renal carcinoma, represent an extensive and substantial pressure on health, primarily among aged population. Due to asymptomatic development of the disease and limitations of conventional methods of diagnosis such as PSA testing, digital rectal examination, cystoscopy, computed tomography, magnetic resonance imaging, and biopsy, early detection of urological cancers is difficult. These approaches are restricted due to poor specificity, risk of overdiagnosis, radiation exposure, procedural invasiveness, and diagnostic uncertainty in distinguishing between malignant and benign lesions despite better survival outcomes. Recent technology and breakthroughs such as multiparametric magnetic resonance imaging (mpMRI), mpMRI/transrectal ultrasonography (TRUS), fusion biopsy, prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT) imaging, dual-energy and photon-counting CT, contrast-enhanced ultrasound, and vesical imaging-reporting and data system (VI-RADS)-based mpMRI have improved tumor diagnosis, staging, and localization. Convergent innovations in cell-free DNA analysis, nanotechnology-assisted assays, molecular biomarkers, radiomics, and AI- driven image analysis have enhanced clinical decision-making and risk assessment. Altogether, these developments are accelerating the transition of urological oncology to be more precise, customized diagnostic frameworks, and less invasive. This chapter highlights current advancements in the detection and diagnosis of urological cancers, focusing on innovative technologies and evolving diagnostic frameworks aimed at improving accuracy, early identification, and clinical decision-making.